Endocrinology
Congress Materials
As part of our commitment to addressing unmet medical needs, Corcept investigates approved products and pipeline compounds and indications. Corcept presents its research at major congress events globally.
The content contained herein is for your information only. No reproduction, alteration, or distribution of this information is permitted. The safety and efficacy of investigational compounds or investigational uses of marketed products have not been established. These uses have not been approved by the US Food and Drug Administration or other regulatory authorities.
Access Corcept congress presentations below.
Filter by:
American Society for Preventative Cardiology
2026
Prevalence of Hypercortisolism in Individuals With Resistant Hypertension and Cardiovascular Disease
Taub PR, Al Dhaybi O, Aroda VR, et al
Heart in Diabetes
2026
Prevalence of Endogenous Hypercortisolism in Individuals With Resistant Hypertension Stratified by Kidney Function: Results From the MOMENTUM Study
DeFronzo RA, Aroda VR, Basile JN, et al
Annual Meeting of The Endocrine Society
2026
Characterization of Individuals With Resistant Hypertension and Post-Dexamethasone Suppression Test Cortisol <1.2, 1.2–1.8, and >1.8 μg/dL: Results From the MOMENTUM Study
Eilerman B, Taub PR, Al Dhayabi O, et al
American Diabetes Association
2026
High Prevalence of Endogenous Hypercortisolism in Patients With Type 2 Diabetes and Resistant Hypertension: Results From the MOMENTUM Study
Umpierrez G, Aroda VR, Budoff M, et al
American Diabetes Association
2026
Effects of Mifepristone in People With Difficult-to-Control T2D and Hypercortisolism on GLP-1 RAs
Sloan LA, Aroda VR, Busch RS, et al
American Association of Clinical Endocrinology
2026
Relacorilant Treatment Improves Glycemic Control Among Individuals With Cushing Syndrome (Endogenous Hypercortisolism) and Hyperglycemia on Glucagon-Like Peptide-1 Receptor Agonists: Insights From a Phase 3 Study
Silverstein JM, Dobri GA, Elenkova A, et al
Annual Meeting of The Endocrine Society
2026
Endogenous Hypercortisolism in Individuals With Resistant Hypertension and Difficult-to-Control Type 2 Diabetes: Results From Two Large, Prospective Studies
DeFronzo RA, Aroda VR, Auchus RJ, et al
American College of Cardiology
2026
Prevalence and Clinical Impact of Hypercortisolism in Patients With Resistant Hypertension: Primary Results From the MOMENTUM Study
Bhatt DL
American Association of Clinical Endocrinology
2026
Co-secretion of Cortisol and Aldosterone in Individuals With Resistant Hypertension: Results From the MOMENTUM Trial
Sloan LA, Aroda VR, Bhatt DL, et al.
American Diabetes Association
2025
A New Cause of Diabetes That Affects ~1.25M Americans: Who Woulda Thought?
DeFronzo RA
American Diabetes Association
2025
Design of the CATALYST Trial and Prevalence Results
Aroda VR
American Diabetes Association
2025
CATALYST Implications—A New Paradigm for Understanding and Treating Type 2 Diabetes
Buse JB
European Association for the Study of Diabetes
2025
Mifepristone, a Glucocorticoid Receptor Antagonist, Reduced HbA1c and Body Weight in Difficult-to-control Type 2 Diabetes with Hypercortisolism: The CATALYST Prevalence and Treatment Trial
RA DeFronzo, V Fonseca, VR Aroda et al
European Association for the Study of Diabetes
2025
Difficult-to-Control Type 2 Diabetes and a Post-Dexamethasone Suppression Test Cortisol of 1.2–1.8 µg/dL: Findings From a Large Prospective Study
Busch RS, Auchus RJ, Bailey T, et al
Association of Diabetes Care & Education Specialists
2025
Final Results of the CATALYST Trial
DeFronzo RA, Fonseca V, Aroda VR
Association of Diabetes Care & Education Specialists
2025
Characterization of Individuals With Difficult-to-Control Type 2 Diabetes and Post-Dexamethasone Suppression Test Cortisol Values <1.2, 1.2–1.8, and >1.8 μg/dL: Findings From the CATALYST Part 1 Study
Auchus RJ, Bailey T, Blonde L, et al
Annual Meeting of The Endocrine Society
2025
The Design of MOMENTUM: A Prospective Study of the Prevalence of Endogenous Hypercortisolism in Individuals With Resistant Hypertension
Plutzky J, Auchus RJ, Basil JN, et al
Annual Meeting of The Endocrine Society
2025
Efficacy and Safety of Relacorilant in Individuals With Adrenal Hypercortisolism: Results From the Phase 3 GRACE and GRADIENT Studies
Dischinger U, Al-Karadsheh A, Badiu C, et al
Annual Meeting of The Endocrine Society
2025
Effects of Relacorilant on Body Weight and Body Composition in Patients With Endogenous Hypercortisolism in the Phase 3 GRACE and GRADIENT Studies
Hamidi O, Auchus RJ, Busch RS, et al
Pituitary Society Congress
2025
Effects of Relacorilant on Pituitary Tumor Volume in Patients With Cushing Disease: Results From the Phase 3 GRACE Study
Dobri GA, Arnaldi G, Auchus RJ, et al
Heart in Diabetes
2025
The Design of MOMENTUM: A Prospective Study of the Prevalence of Endogenous Hypercortisolism in Individuals With Resistant Hypertension
Plutzky J, Auchus RJ, Basile JN, et al
Heart in Diabetes
2025
High Medication and Cardiovascular Disease Burden in Individuals With Difficult-to-Control Type 2 Diabetes: Clinical Characteristics From the CATALYST Study
DeFronzo RA, Buse J, Eilerman B, et al
American Association of Clinical Endocrinology
2025
Efficacy and Safety of Relacorilant in Patients With Adrenal Hypercortisolism: Results From a Phase 3 Study
Hamrahian A, Aresta C, Badiu C, et al
American Association of Clinical Endocrinology
2025
Characterization of Patients With Difficult-to-Control Type 2 Diabetes and a Post–Dexamethasone Suppression Test Cortisol of 1.2–1.8 μg/dL: Findings From a Large Prospective Study
Busch RS, Auchus RJ, Bailey T
American Association of Clinical Endocrinology
2025
A Comprehensive Safety Assessment of Relacorilant: Insights From Phase 2 and Phase 3 Trials in Patients With Endogenous Hypercortisolism
Hannoush ZC, Badiu C, Mangas Cruz MA, et al
American Association of Clinical Endocrinology
2025
Clinical Learnings Based on a Case Series: Considerations for Identifying and Treating Hypercortisolism in Patients with Diabetes
Lucci CP, McCoy G
European Congress of Endocrinology
2025
Medical Treatment of Hypercortisolism with Relacorilant: Final Results of the Phase 3 GRACE Study
Pivonello R, Arnaldi G, Auchus RJ, et al
American Association of Clinical Endocrinology - Middle East & North Africa
2025
Open-label Extension Study Evaluating the Safety and Efficacy of Long-term Use of Relacorilant in Patients With Endogenous Hypercortisolism (Cushing Syndrome): Results from the First Interim Analysis
Badiu C, Auchus RJ, Bancos I, et al
European Congress of Endocrinology
2024
Open-label Extension Study Evaluating the Safety and Efficacy of Long-term Use of Relacorilant in Patients With Endogenous Hypercortisolism (Cushing Syndrome): Interim Analysis Results
Badiu C, Auchus R, Bancos I, et al
Heart in Diabetes
2024
Medical Treatment of Hypercortisolism with Relacorilant: Final Results of the Phase 3 GRACE Study
Pivonello R, Arnaldi G, Auchus RJ, et al
Heart in Diabetes
2024
Hypercortisolism Impact on Hypertension and Hyperglycemia and Beyond
DeFronzo R
World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease
2024
Prevalence of hypercortisolism in patients with difficult-to-control type 2 diabetes and cardiovascular disease: results from CATALYST
Fonseca V, Aroda VR, Budoff M, et al.
World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease
2024
Prevalence of hypercortisolism in patients with difficult-to-control type 2 diabetes and high blood pressure: Results from CATALYST
Handelsman, Y, Aroda VR, Bailey T, et al.
World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease
2024
Relacorilant improved blood pressure and maintained other cardiometabolic improvements in long-term study in patients with endogenous hypercortisolism (Cushing syndrome).
Auchus RJ, Gilis-Januszewska A, Badiu C, et al
World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease
2024
Open-label extension study evaluating the safety and efficacy of long-term use of relacorilant in patients with endogenous hypercortisolism (cushing syndrome): interim analysis results
Badiu C, Auchus RJ, Bancos I, et al
World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease
2024
Medical treatment of hypercortisolism with relacorilant: final results of the phase 3 grace study
Piconello R, Arnaldi G, Auchus RJ, et al
American Association of Pharmaceutical Scientists
2024
A Phase 1, Open-Label, Drug-Drug Interaction Study Designed to Evaluate the Effect of Relacorilant on the Pharmacokinetics of the Sensitive P-gp Substrate Dabigatran Etexilate in Healthy Subjects
Kunta J, Donaldson K, Hynt HJ, et al.
American Association of Clinical Endocrinology - Middle East & North Africa
2024
Relacorilant Maintained Hypertension Improvement in Long-term Follow-up of Patients With Endogenous Hypercortisolism (Cushing Syndrome)
Gilis-Januszewska A, Badiu C, Ranetti A-E, et al
Annual Meeting of The Endocrine Society
2024
Results From Grace, a Phase 3 Double-blind, Randomized-withdrawal Study of the Selective Glucocorticoid Receptor Modulator Relacorilant for the Treatment of Endogenous Hypercortisolism (Cushing Syndrome)
Pivonello R, Arnaldi G, Auchus RJ, et al
American Association of Clinical Endocrinology
2024
Rapid Clinical Improvements in a Patient with Difficult-to-Control Type 2 Diabetes by Addressing Underlying Hypercortisolism with Mifepristone
Rizzo K, Ali J
The Italian Society of Endocrinology
2023
Impact of Surgery or Medical Treatment With the Selective Glucocorticoid Receptor Modulator Relacorilant on Hypercoagulopathy in Patients With Cushing Syndrome
Simeoli C, DiPaola, Stigliano A, et al
Annual Meeting of The Endocrine Society
2023
Impact of Surgery or Medical Treatment With the Selective Glucocorticoid Receptor Modulator Relacorilant on Hypercoagulopathy in Patients With Cushing Syndrome
Simeoli C, DiPaola, Stigliano A, et al
Annual Meeting of The Endocrine Society
2023
A Phase 4 Study of Hypercortisolism in Patients with Difficult-to-Control Type 2 Diabetes Despite Receiving Standard-of-Care Therapies, Assessing Prevalence and Treatment with Mifepristone
Frias JP, Auchus, RJ, Bancos I, et al
Heart in Diabetes
2023
A Phase 4 Study of Hypercortisolism in Patients with Difficult-to-Control Type 2 Diabetes Despite Receiving Standard-of-Care Therapies, Assessing Prevalence and Treatment with Mifepristone
Frias JP, Auchus, RJ, Bancos I, et al
European Congress of Endocrinology
2023
Impact of Surgery or Medical Treatment With the Selective Glucocorticoid Receptor Modulator Relacorilant on Hypercoagulopathy in Patients With Cushing Syndrome
Simeoli C, DiPaola, Stigliano A, et al
European Congress of Endocrinology
2023
An Open-Label Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Endogenous Cushing Syndrome
Badiu C, Mariash C, Kautzky-Willer A, et al
American Association of Clinical Endocrinology
2023
Absence of QT Prolongation Associated with Relacorilant, a Selective Glucocorticoid Receptor Modulator in Development for the Treatment of Cushing Syndrome
Donegan DM, Pivonello R, Stigliano A, et al
American Association of Clinical Endocrinology
2023
A Phase 4 Study of Hypercortisolism in Patients with Difficult-to-Control Type 2 Diabetes Despite Receiving Standard-of-Care Therapies, Assessing Prevalence and Treatment with Mifepristone
Frias JP, Auchus, RJ, Bancos I, et al
Annual Meeting of The Endocrine Society
2022
Impact of mifepristone on liver function and liver steatosis in patients with Cushing syndrome
East HE, Moraitis AG, Belanoff J
Annual Meeting of The Endocrine Society
2022
Favorable liver safety profile of the selective glucocorticoid receptor modulator relacorilant in healthy and hepatically impaired adults and in patients with Cushing syndrome
Moraitis AG, Custodio JM, Tudor CT
European Congress of Endocrinology
2022
Favorable liver safety profile of the selective glucocorticoid receptor modulator relacorilant in healthy and hepatically impaired adults and in patients with Cushing syndrome
Moraitis AG, Custodio JM, Tudor CT
American Association of Clinical Endocrinology
2022
Mifepristone use in hypercortisolism from an unknown source: a case study
Brown DR, Ray R
Annual Meeting of The Endocrine Society
2021
Relacorilant With Pembrolizumab: A Phase 1b, Open-Label Study of a Selective Glucocorticoid Receptor Modulator Combined With a Checkpoint Inhibitor for Patients With Adrenocortical Carcinoma With Excess Glucocorticoid Production
Habra MA, Hammer GD, Kebebew E, Worden FP, Raj N, Hallanger-Johnson JE, Grauer A, Moriatis A
American Association of Clinical Endocrinology
2021
Prevalence of Hypercortisolism in Patients With Adrenal Adenoma(s) and Type 2 Diabetes Mellitus: Findings From an Electronic Medical Records (EMR) Search
Sachmechi I, Salam S, Umair M, Tarnowski KW
American Association of Clinical Endocrinology
2021
Use of Mifepristone in a Hypercortisolemic Patient With End-Stage Renal Disease on Hemodialysis
Coo AW, Ray R
Annual Meeting of The Endocrine Society
2020
GRADIENT: A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study to Assess the Efficacy and Safety of a Selective Glucocorticoid Receptor Modulator, Relacorilant, in Patients With Autonomous Cortisol Secretion Due to Cortisol-Secreting Adrenal Adenoma(s)/Hyperplasia
Auchus, RJ, Grauer A, Moriatis AG
European Congress of Endocrinology
2020
A Double-Blind, Randomized, Placebo-Controlled Phase 3 Study to Assess the Efficacy and Safety of Relacorilant, a Selective Glucocorticoid Receptor Modulator, in Patients With Hypercortisolism Due to Cortisol-Secreting Adrenal Adenoma(s)/Hyperplasia
Chiodini Grauer A, Moriatis AG, Terzolo M
European Congress of Endocrinology
2020
Excess Glucocorticoid Activity May Suppress Tumor Immune Activity in Adrenocortical Carcinoma
Greenstein AE, Habra MA, Mura M, Biernat P, Piatek MJ, Grauer A, Shepherd SP
Annual Meeting of The Endocrine Society
2019
A Randomized-Withdrawal, Placebo-Controlled, Phase 3 Study to Assess the Efficacy and Safety of Selective Glucocorticoid Receptor Antagonist, Relacorilant, in Patients With Cushing Syndrome (GRACE Study)
Auchus RJ, Findling JW, Moriatis AG
Annual Meeting of The Endocrine Society
2019
Sustained Clinical Improvement After Discontinuation of Mifepristone: Unexpected Remission of Hypercortisolism
Anderson R, Pesa N, Kassar A
Annual Meeting of The Endocrine Society
2019
Anticipating Hypokalemia in Patients With ACTH-Dependent Cushing Syndrome Treated With Mifepristone: Utilization of Cortisol and ACTH Levels to Identify At-Risk Patients
Moraitis AG, Nguyen
Annual Meeting of The Endocrine Society
2019
Tumor Shrinkage With Preoperative Relacorilant Therapy in Two Patients With Cushing Disease due to Pituitary Macroadenomas
Terzolo M, Iacuaniello D, Pia A, Adriano P, Moriatis A, Pivonello R
American Association of Clinical Endocrinology
2019
Improvement in Muscle Strength and Psychiatric Symptoms in a Patient With Persistent Cushing Disease Treated With Mifepristone
Yacoub T, Palaniswamy K
American Association of Clinical Endocrinology
2019
Clinical Consequences of an Untreated Cortisol-Producing Adrenal Adenoma: A 10-Year History
Jerkins TW, Jerkins RK, Ray R
American Association of Clinical Endocrinology
2019
Prevalence of Hypercortisolism in Patients With Type 2 Diabetes Mellitus With Incidentally Found Adrenal Adenomas: An Interim Analysis
Sachmechi I, Alkomos MF, Zarghamravanbaksh P, Mahendhar R, Palaniswamy K
American Association of Clinical Endocrinology
2019
Mifepristone Provides Beneficial Clinical Improvement in Two Cushing Disease Cases in a Community Endocrinology Practice
Iweha C, Chavez D
American Association of Clinical Endocrinology
2019
Efficacy and Safety of the Selective Glucocorticoid Receptor Modulator, Relacorilant (up to 400 mg/day), in Patients With Endogenous Hypercortisolism: Results From an Open-Label Phase 2 Study
Pivonello R, Kargi A, Ellison N, Moriatis A, Terzolo M
Annual Meeting of The Endocrine Society
2018
Mifepristone therapy prior to pituitary surgery in Cushing disease prevented need for long-term glucocorticoid replacement
Sack PA Smith JJ
Annual Meeting of The Endocrine Society
2018
A curious case of biochemical and clinical remission after treatment with mifepristone, a glucocorticoid receptor antagonist
Cohan P, Kelly DF, Lim PJ